稳定性冠心病的初始侵入性或保守策略
该研究为随机对照试验,纳入5179例稳定性冠心病伴中重度缺血患者,随机分配至初始侵入性策略(血管造影及可行时血运重建联合药物治疗)或初始保守策略(单纯药物治疗,治疗失败时行血管造影)。中位随访3.2年,主要终点(心血管死亡、心肌梗死、不稳定型心绞痛住院、心力衰竭住院或复苏后心脏骤停的复合终点)在侵入性策略组发生318例、保守策略组352例;6个月累积事件率侵入性策略组5.3% vs 保守策略组3.4%(差异1.9个百分点,95%CI 0.8至3.0),5年累积事件率分别为16.4%和18.2%(差异-1.8个百分点,95%CI -4.7至1.0)。关键次要终点结果相似。全因死亡侵入性策略组145例 vs 保守策略组144例(HR 1.05,95%CI 0.83至1.32)。结论:未发现初始侵入性策略较初始保守策略降低缺血性心血管事件或全因死亡风险,试验结果对心肌梗死定义敏感。
要点
- 稳定性冠心病伴中重度缺血患者,初始侵入性策略较初始保守策略未降低主要复合终点事件风险(5年累积事件率16.4% vs 18.2%,差异-1.8个百分点,95%CI -4.7至1.0)。
- 6个月时主要终点累积事件率侵入性策略组5.3% vs 保守策略组3.4%(差异1.9个百分点,95%CI 0.8至3.0)。
- 全因死亡侵入性策略组145例 vs 保守策略组144例(HR 1.05,95%CI 0.83至1.32)。
- 主要终点结果对心肌梗死定义敏感,二次分析显示更多围手术期心肌梗死,临床重要性不确定。
- 关键次要终点(心血管死亡或心肌梗死)结果与主要终点相似。
适用人群与场景
- 稳定性冠心病伴中重度缺血患者,随机纳入5179例。
处置流程与药物剂量
- 初始侵入性策略:血管造影及可行时血运重建,联合药物治疗。
- 初始保守策略:单纯药物治疗,药物治疗失败时行血管造影。
研究设计与关键结果
- 随机对照试验,纳入5179例稳定性冠心病伴中重度缺血患者,随机分配至初始侵入性策略(血管造影及可行时血运重建联合药物治疗)或初始保守策略(单纯药物治疗,失败时血管造影)。
- 中位随访3.2年,主要终点(心血管死亡、心肌梗死、不稳定型心绞痛住院、心力衰竭住院或复苏后心脏骤停的复合终点)侵入性策略组318例 vs 保守策略组352例。
- 6个月累积事件率侵入性策略组5.3% vs 保守策略组3.4%(差异1.9个百分点,95%CI 0.8至3.0);5年累积事件率分别为16.4%和18.2%(差异-1.8个百分点,95%CI -4.7至1.0)。
- 关键次要终点(心血管死亡或心肌梗死)结果相似。
- 全因死亡侵入性策略组145例 vs 保守策略组144例(HR 1.05,95%CI 0.83至1.32)。
- 主要终点结果对心肌梗死定义敏感;二次分析显示更多围手术期心肌梗死,临床重要性不确定。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于稳定性冠心病伴中重度缺血患者,初始侵入性策略较初始保守策略未降低缺血性心血管事件或全因死亡风险,支持与患者讨论后个体化选择初始策略。
- 解读结果时需注意主要终点对心肌梗死定义敏感,围手术期心肌梗死的临床重要性不确定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain.
METHODS: We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial infarction.
RESULTS: Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, respectively (difference, -1.8 percentage points; 95% CI, -4.7 to 1.0). Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial infarctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32).
CONCLUSIONS: Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used. (Funded by the National Heart, Lung, and Blood Institute and others; ISCHEMIA ClinicalTrials.gov number, NCT01471522.).
参考来源
- Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020. PMID: 32227755. doi:10.1056/NEJMoa1915922
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。